Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Breast Neoplasms 15Leukemia 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myeloid, Chronic-Phase 10Recurrence 8Prostatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 7Neoplasm Metastasis 6Leukemia, Lymphocytic, Chronic, B-Cell 6Melanoma 5Burkitt Lymphoma 5Pancreatic Neoplasms 4Leukemia, Myeloid, Acute 4Glioblastoma 4Blast Crisis 4Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Neoplasms 3Lymphoma 3Gliosarcoma 3Sarcoma 2Salivary Gland Neoplasms 2Rhabdomyosarcoma 2Rectal Neoplasms 2Polycythemia Vera 2Oligodendroglioma 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

Sorafenib 52pembrolizumab 26Nivolumab 20Bevacizumab 19Radiosurgery 17Doxorubicin 12atezolizumab 9Erlotinib Hydrochloride 9lenvatinib 8cabozantinib 7Magnetic Resonance Spectroscopy 7tremelimumab 6durvalumab 6Ramucirumab 6Radiofrequency Ablation 6Cisplatin 6Sunitinib 5tislelizumab 4regorafenib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fluorouracil 4Everolimus 4Capecitabine 4nintedanib 3fluoromisonidazole 3carotuximab 3bavituximab 3Tomography, X-Ray Computed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Hepatocellular × Dasatinib × Clear all
NCT00459108 2018-04-19

Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
25 enrolled 7 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡